Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

Rhea-AI Summary

Protagonist Therapeutics, Inc. announced that their CEO will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference in New York City on February 7-8, 2024. The presentation will take place on February 8 at 9:00-9:25 A.M. EST at St. Regis New York. A replay of the presentation will be available on the company's website.

NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference being held in New York City on February 7-8, 2024.

Event: 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference Date: February 7-8, 2024
Presentation: Thursday, February 8 at 9:00-9:25 A.M. EST
Location: St. Regis New York, Two E. 55th Street, New York, NY 10022

A replay of the company presentation will be published to the Events & Presentations section of the Protagonist corporate website: https://www.protagonist-inc.com/events-presentations.

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary peptide technology platform. Protagonist scientists jointly discovered oral peptide PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with Johnson & Johnson and followed it through IND-enabling pre-clinical and Phase 1 studies, with Johnson & Johnson assuming responsibility for further clinical development. Rusfertide, a peptide-mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study was unblinded, showing positive results and is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains all worldwide development and commercialization rights to rusfertide.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at protagonist-inc.com.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061

SOURCE: Protagonist Therapeutics, Inc.

View the original press release on accesswire.com

FAQ

When is the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference taking place?

The conference is scheduled for February 7-8, 2024.

Where will the presentation by Protagonist Therapeutics, Inc. take place?

The presentation will take place at St. Regis New York, Two E. 55th Street, New York, NY 10022.

When will the presentation by Protagonist Therapeutics, Inc. be held?

The presentation is scheduled for Thursday, February 8 at 9:00-9:25 A.M. EST.

Where can a replay of the presentation be found?

A replay of the presentation will be available on the company's website in the Events & Presentations section.